Background
Plasmodium vivax is a risk factor for severe anaemia, among patients in vivax-endemic areas [
1-
7]. Increasing evidence has established an association between vivax malaria, severe anemia, and death [
8-
16]. The pathogenesis of severe anaemia in vivax-malaria remains unclear and is likely caused by multiple underlying factors. These include the destruction of parasitized erythrocytes, ineffective erythropoiesis or dyserythropoiesis, and immunity associated with disease. Evidence for dyserythropoiesis, pancytopenia and degradation of erythroblasts was found in bone marrow from patients infected with
P. vivax parasites [
17-
21]. Moreover,
in vitro cultures of erythroid cells derived from haematopoietic stem cells has demonstrated that
P. vivax is able to directly inhibit erythroid cell proliferation and differentiation [
22]. The molecular mechanisms underlying the suppression of erythropoiesis by
P. vivax are remarkably complex and poorly understood.
The phosphoproteome strategy is alternative proteomic method that allows investigation into the molecular mechanisms of signal transduction pathways [
23]. The separation and enrichment of phosphoproteins utilizes metal ion or TiO
2 embedded columns prior to the identification and determination of phosphoproteins under liquid chromatography–mass spectrometry (LC-MS) based techniques [
24,
25]. Many molecular pathways in eukaryotic cells are modulated by specific signaling proteins that are controlled, by phosphorylation and dephosphorylation, through the activity of kinase and phosphatase enzymes. This post-translational control of eukaryotic cellular machinery is a hallmark of pathways that respond to different stimuli. The level of protein phosphorylation at specific sites varies from less than 1% to greater than 90%, depending on conditions [
26]. The regulation of complex and dynamic signal transduction proteins contributes to the destination of targeting proteins and the signal transduction of cell growth, and exposure to parasites can also influence signaling pathways. This occurs through specific modulation of regulatory proteins during the host-pathogen interaction, especially proteins with roles in pathogenesis [
27]. The specific mechanism involved in the suppression of erythroid development by
P. vivax has not been elucidated. However, it is known that during parasite exposure, suppressed erythroid development is a key aspect in the pathophysiology of anaemia. Here, this study describes the first comparative phosphoproteome of erythroid cells, derived from human haematopoietic stem cells, exposed to proteins of
P. vivax. This analysis utilized IMAC phosphoprotein isolation, directly coupled with LC MS/MS analysis. Interestingly, the phosphoprotein ezrin, involved in the regulation of cytoskeleton during cell development, was identified using this procedure. Ezrin, a member of the ezrin, radixin, and moesin (ERM) subfamily of cytoskeletal proteins and is conserved both functionally and structurally in mammalian cells [
28]. Through the regulation of the cytoskeleton ezrin has a role in several cellular processes, such as maintenance of survival, cytokinesis, adhesion, membrane dynamics, motility, and integration of membrane transport with signaling pathways [
29]. Usually, ezrin is present in an inactive conformation and functions as a crosslinker between the plasma membrane and cytoskeleton [
30]. Two regions of ezrin, the N-terminal and C-terminal domains are involved in the active conformation. The N-terminal domain binds to phosphatidylinositol 4,5-biphosphate, which facilitates phosphorylations of threonine 567 (Thr567) in the C-terminal domain [
28]. Rho kinase and protein kinase C (PKC) are capable of phosphorylating the C-terminal threonine in ezrin, promoting the formation of the F-actin binding site in active conformation [
31-
35]. This study has identified the involvement of the cytoskeleton protein ezrin in the inhibitory effect of
P. vivax on erythroid cell growth, leading to ineffective erythropoiesis. The molecular mechanism characterized in this study, relevant to ineffective erythropoiesis, should have utility in the development of therapeutic strategies for severe malarial anaemia.
Methods
Parasite preparation
Plasmodium vivax parasites from patient blood with 0.05-0.2% parasitaemia, as determined by examining thick and thin blood smears, were collected. The ethical and methodological aspects of this study for parasite collection from patients attending the malaria clinic in Tha Sae, Chumpon Province, Thailand (MU-IRB 2012/170.2511) have been approved by the Mahidol University Institutional Review Board, Mahidol University, Bangkok, Thailand. Infected erythrocytes (IE) were separated from patient blood using a 60% Percoll solution as previously described [
36]. Briefly, 20 ml of whole blood from patients were collected and passed through a Plasmodipur filter (Euro-Diagnostic B.V., Netherlands) to remove white blood cells. To separate IE, patient blood, after filtration, was diluted 1:20 with RPMI1640 (Invitrogen®, CA, USA), layered on 60% Percoll, and centrifuged at 1,200 g for 20 min at 20°C. The purity of IE after isolation was 95%, containing 80% schizonts and 20% other stages. The isolated IEs were used as lysed cells prepared by freezing and thawing as previously described [
22].
Isolation of cord blood CD 34+ cells and culture conditions
Haematopoietic stem cells (HSCs)/CD 34
+ cells were isolated from normal human umbilical cord blood as previously described [
22]. Cord blood collected from normal full-term deliveries at Ramathibodi Hospital (ID 04-52-39) was approved by the Ethical Committee of Research on Human Beings of the Ramathibodi Hospital, Faculty of Medicine, Mahidol University. Briefly, HSCs/CD34
+ cells from cord blood were isolated using a CD 34 isolation kit with magnetic microbead Mini-MACS columns (Miltenyi Biotech, Geramany). The purity of CD34
+ cells after isolation was 97% as determined by flow cytometry analysis.
Growing erythroid cells (gECs), derived from HSCs/CD34
+ cells, at a density of 5 x 10
5 cell/well in 24-well tissue culture plates (Corning Incorporated Costar®, NY, USA) were cultured in 1 ml of complete medium containing Stemline II medium (Sigma-Aldrich Corporation, Missouri, USA) supplemented with cytokines as previously described [
36]. Lysates of IE or uninfected erythrocytes (UE) from normal donor blood were added to gEC cultures, at a ratio of 1:10 (gEC:IE/UE), on day 5 and cultured at 37°C in 5% CO
2 for 24, 48, 72 h. Viable cells were determined by trypan blue dye exclusion and dead cells were stained with 2 μg/ml propidium iodide (eBioscience) and analysed by flow cytometry.
Cell cycle analysis
gECs exposed to IE/UE for 48 and 72 h were washed with PBS and fixed with 70% cold ethanol overnight at -20°C. After fixed cells were washed with PBS, cells were added with 5 μg/ml RNase A (Geneaid Biotech Ltd., Taiwan), stained with 20 μg/ml propidium iodide (eBioscience) and incubated for 30 min at 37°C in dark. DNA analysis was performed on a FACS Canto™ flow cytometer (Becton Dickinson). Cell cycle analysed by BD FACSDiva software version 4.1 (Becton Dickinson) was used to determine the percentages of cells in the different cell cycle phases. Experiments were performed five independent times and values are shown as means ± S.D.
Preparation of phosphoprotiens
Phosphoproteins were prepared from gECs, after exposure to IE/UE lysates, using Pierce Phosphoprotein enrichment kit (Thermo Scientific, Pierce Biotechnology, IL, USA) followed the manufacturer’s instructions. Briefly, 5 x 10
6 cells were added to 200 μl of lysis/binding/wash buffer with CHAPS and 1X phosphatase inhibitors (phosphatase inhibitor cocktail 100X, Roche, UK) and lysed on ice by sonication (Sonics Vibra cell,sonics & materials INC., USA) with amplitude 70% utilizing 15 cycles of 2 sec disruption followed by 2 sec on ice. Following centrifugation (Tomy MX-305 high speed refrigerated microcentrifuge, CA, USA), 10,000 g at 4°C for 10 min, supernatants from cell lysates were collected and proteins concentrations were determined by Lowry method [
37].
For phosphoprotein enrichment, cell lysates were adjusted to a concentration to 0.5 mg/ml in lysis/binding/wash buffer without CHAPS and applied to the column. Columns were inverted to mix for 30 min at 4°C and then washed three times with lysis/binding/wash buffer with CHAPS using centrifugation (Allegra X-22R centrifuge, Beckman Coulter, Inc, USA) at 1,000 g for 1 min at 4°C. One millimetre of elution buffer, consisting of 75 mM sodium phosphate, 500 mM sodium chloride, pH 7.5, was added to each column and then incubated at room temperature, with agitation for 3 min. The eluted proteins were collected by centrifugation at 1,000 g for 1 min at 4°C, and this step was repeated four times. The pool of eluted proteins was concentrated using a Pierce concentrator (Thermo Scientific). Briefly, 4 ml of each sample of eluted proteins was placed into the upper chamber of the concentrator followed by centrifugation at 7,000 g for 30 min at 4°C. The concentrated proteins, approximately 100-200 μl, were collected from the upper chamber and stored at -80°C. In the final step, salts and other molecules (<1,000 Da) were removed using Zeba™ spin desalting columns (Thermo Scientific). One hundred microlitres of each sample was applied to columns and then centrifuged at 700 g for 30 sec. The desalted samples were collected and the proteins content of each sample was determined by the Lowry method and used for phosphoprotein analysis.
Phosphoprotein analysis
After desalting, 4 μg of phosphoproteins in 10 mM ammonium bicarbonate were reduced with 10 mM DTT (Dithiotheitol) for 30 min at 60°C, alkylated with 15 mM IAA (iodoacetamide) at room temperature for 30 min, and digested with sequencing grade trypsin (Promega, Geramany) for 16 h at 37°C. Tryptic phosphopeptides were diluted with 0.1% formic acid to final concentration of 0.25 μg/μl and centrifuged 10,000 rpm at room temperature for 10 min. Phosphopeptide samples were injected into a NanoAcquity system (Waters Corp., Milford, MA) equipped with a Symmetry C18 5 μm, 180-μm x 20-mm Trap column and a BEH130 C18 1.7 μm, 100-μm x 100-mm analytical reversed phase column (Waters Corp., Milford, MA). The samples were initially transferred with an aqueous 0.1% formic acid solution (mobile phase A) to the trap column with a flow rate of 15 μl/min for 1 min. The peptides were separated with a gradient of 15-50% mobile phase B in acetonitrile with 0.1% formic acid over 15 min at a flow rate of 600 nl/min followed by a 3 min rinse with 80% of mobile phase B. The column temperature was maintained at 35°C. The lock mass was delivered from the auxiliary pump of the NanoAcquity system with a constant flow rate of 500 nl/min with 200 fmol/μl of [Glu1] fibrinopeptide B delivered to the reference sprayer of the NanoLockSpray source of the mass spectrometer. All samples of tryptic peptides were analysed by using a SYNAPT™ HDMS mass spectrometer (Waters Corp., Manchester, UK), which was operated in the V-mode of analysis with a resolution of at least 10,000 full-width half-maximum, using positive nanoelectrospray ion mode. The time-of-flight analyzer of the mass spectrometer was externally calibrated with [Glu1] fibrinopeptide B from m/z 50 to 1600 with acquisition lock mass corrected using the monoisotopic mass of the doubly charged precursor of [Glu1] fibrinopeptide B. The reference sprayer was sampled with every 20 sec. Accurate mass LC-MS data were acquired with data direct acquisition mode. The energy trap was set at the collision energy of 6 V. In the transfer collision energy control, low energy was set at 4 V. The quadrupole mass analyzer was adjusted such that ions from m/z 300 to 1800 were efficiently transmitted. The MS\MS survey was over range from 50 to 1990 Da and scan time was 0.5 sec.
Protein identification
The differential quantitation of proteins and peptides based on the MS signal intensities of individual LC-MS samples was analysed using DeCyder MS differential analysis software (DeCyderMS, GE Healthcare) [
38,
39]. Acquired LC-MS raw data were converted and the PepDetect module was used for automated peptide detection, charge state assignments, and quantitation based on the peptide ions signal intensities in MS mode. The analysed MS/MS data from DeCyderMS were submitted for database search using the Mascot software (Matrix Science, London, UK) [
40]. For protein identification, data was compared against the NCBI
Homo sapiens database with the following parameters: enzyme (trypsin); variable modifications (carbamidomethyl, oxidation of methionine residues); mass values (monoisotopic); protein mass (unrestricted); peptide mass tolerance (1.2 Da); fragment mass tolerance (±0.6 Da), peptide charge state (1+, 2+ and 3+) and max missed cleavages.
All MS/MS data were compared against the human protein set using Swissprot protein database. The heatmap visualization was constructed using the web-based analysis MEV program [
41] and the protein cluster was analysed by distance metric selection with Pearson correlation parameters calculate K-Means. Different levels of phosphoproteins were analysed using the significant
t-test at
P-value ≤ 0.05. The gene ontology analysis was performed with UniprotKB (protein knowledgebase) [
42] and PANTHER (classification system) [
43] databases for biological processes, molecular function and classification. The mapping of protein-protein interactions was conducted using data visualization with statistical analysis at a low confidence score in the STRING database (known and predicted protein-protein interactions) [
44]. Gene biological categorization was performed and selected at
P-value ≤ 0.01. Analysis of the protein-protein interaction network was performed using the KEGG (Kyoto Encyclopedia of Genes and Genomes) PATHWAY database [
45,
46].
Immunofluorescence assays
The distribution of threonine-phosphorylated ezrin and ezrin in gECs after exposure to IE/UE and in control media was verified by immunofluorescence. Cells were fixed in 4% formaldehyde in PBS (phosphate buffer saline) at 4°C for 20 min, washed with PBS, permeabilized with 0.1% Triton X-100 in PBS for 10 min, and blocked in 2% human serum in PBS for 20 min at room temperature. Mouse anti-ezrin (Abcam®, Cambridge, UK) and rabbit anti-phospho-ezrin (Thr567)/radixin (Thr564)/mosin (Thr41A3) ERM (Cell Signaling Technology, Danvers, MA, USA) antibodies, diluted in 1% human serum/PBS at a ratio 1:100, were added and incubated at room temperature for 1.5 h. Cells were incubated with goat anti-rabbit and anti-mouse antibodies, conjugated with Alexa Fluor green 488 and Alexa Fluor Red 594 (Molecular probes), respectively, diluted in 2% human serum/PBS were for 2 h. After washing with PBS, stained cells were mounted with anti-fade medium containing DAPI (Molecular probes). Cells were examined using a laser scanning confocal microscope (LSM 510 Meta, Zeiss, Jena, Germany) with a 63x objective at zoom 2. Immunofluoresence intensity of 1,000 cells from each culture condition was determined using ImageJ 1.48v/Java software [
47]. The mean of intensity from 1,000 cells were presented as intensity ratios, calculated from the intensity of IE/UE-exposed gECs divided by the intensity of gECs in control cultures.
Statistical evaluation
Data for cell growth was analysed using the SPSS program (version 17). The unpaired Mann-Whitney-Wilcoxon test was used to compare means between independent groups for significantly statistic evaluation of cell growth, P-value < 0.01.
Discussion
Anaemia has been frequently observed to be a consequence of vivax infection [
4,
7,
10,
48-
58]. Recently, transmission electron microscope analysis of two vivax malarial cases with symptom of anaemia demonstrated the presence of
P. vivax-infected erythroblasts and subsequent degradation of erythroblasts. Interestingly,
P. vivax parasites were found in bone marrow, but could not be detected in peripheral blood [
17]. Consistent with this observation, an
in vitro study has revealed that
P. vivax can directly inhibit erythroid cell proliferation and differentiation through altered division of erythroid cells [
22]. However, the mechanisms underlying the suppression of erythroid development by
P. vivax appear to be complex and poorly characterized. In this study, phosphoprotein analysis was used to investigate the underlying the suppression of erythroid development by
P. vivax. Using LC-MS/MS analysis in combination with gene ontology information from the human protein database, 44 phosphoproteins from gECs exposed and non-exposed to IE/UE were identified and categorized according to molecular function, biological process and protein class. Interestingly, the relative level of phosphoproteins was significantly lower following exposure of gECs to parasite proteins, compared to non-exposed cells. Phosphoproteins that displayed significant decreases include ezrin, alpha actinin-1 and Rho kinase. These phosphoproteins were determined to be in the same cluster 1 with significantly low level pattern of phosphoproteins and exhibited a similar pattern of abundance in response to IE exposure. These results suggest that the phosphoproteins ezrin, alpha actinin-1 and Rho kinase may have roles in the inhibitory effect on erythroid cell growth and division following
P. vivax exposure. The protein-protein interaction networks determined using the KEGG human protein database revealed that ezrin functions in several cellular pathways, including regulation of actin cytoskeleton.
Ezrin, a member of ERM (ezrin, radixin and moesin) proteins, is localized to cell extension peripheral processes and able to interact with transmembrane proteins and the cytoskeleton. Ezrin functions to regulate cytoskeletal assembly, membrane-protein function and membrane transport [
29,
59,
60]. Recent studies, have implicated ezrin as a signal transducer involved in a wide variety of cellular functions, including cell survival, adhesion, morphogenesis, motility, cytokinesis and cellular proliferation [
61,
62]. Increasing evidence indicates a direct relationship between cell proliferation and the level of ezrin expression in cells [
63-
65]. Microinjection of anti-ezrin antibodies into the cytoplasm blocked the entry of mouse fibroblasts into S phase, confirming the function of ezrin in proliferation [
66]. In response to TNF, ezrin inhibits endothelial cell proliferation through transcriptional repression of cyclin A, a cell cycle regulatory protein [
67]. This study also found that ezrin in erythroid cells appears to function in the regulation of cell growth and division. Erythroid cells with growth inhibited by
P. vivax display low levels of ezrin phosphoprotein.
The phosphorylation of a threonine at residue 567 (T567) is necessary for the active conformation of ezrin and enhances binding with F-actin [
28]. The results of this study also find that phosphorylation of ezrin, possibly at Thr567, is involved in the regulation of erythroid cell growth. Although our analysis identified the position of the phosphorylation site in an ezrin-phosphopeptide as tyrosine 565, the phosphorylation of ezrin threonine 567 was also detected using a specific antibody. A source of error in phosphorylation site localization on peptides is the presence and intensity of ions for these species in the MS/MS spectra [
68]. However, both residues 565 and 567 are contained in the phosphopeptide 563-572 from ezrin, which was detected in this study. It is also possible that the anti-ezrin Thr567 monoclonal antibody may recognize the phosphorylation of Tyr565 as well as Thr567. This antibody was produced using phosphopeptide of human ezrin containing residues 564-568 (K
YK
TL) [
31] and contains both Tyr565 and Thr567. Previous reports have demonstrated the specificity of this antibody for phospho-ezrin Thr567 [
69-
71] but it is not known if it can recognize phosphorylation at other sites.
Three phosphoproteins in this study, ezrin, Rho kinase and alpha actinin-1 are present at significantly low levels in parasite-exposed cells. Investigation of the KEGG PATHWAY database demonstrates that ezrin has important roles in various pathways, particularly, regulation of actin cytoskeleton, which has implications to malaria, as shown in Figure
4c. Ezrin exerts its biological functions through protein-protein interactions and its active form is regulated by Rho kinase/ROCK2, which directly interacts with membrane proteins [
31,
72]. Ezrin binds to adhesion-related proteins with single transmembrane domains such as ICAM-1, CD44 and CD43 through their cytoplasmic tails to modulate cell morphology [
61,
73]. Cytoadhesion molecules such as ICAM1 contribute to cytoadhesive phenotype/rosetting and high intensity of rosetting is found in anaemia cases with
P. vivax infection [
74]. Both ICAM-1 and VCAM-1, soluble adhesion molecules, are detected at high levels in serum from falciparum patients with severe malaria [
75]. This study also found abnormal erythroid cell aggregation in culture of gECs exposed to IE lysates (Additional file
2). Taken together, this suggests that during interaction of
P. vivax proteins with adhesion molecules on erythroid cells, ezrin regulates cell adhesion by connecting membrane adhesion receptors to the actin-based cytoskeleton. This erythroid cell adhesion may contribute to down regulation of erythroid cell production leading to the development of anaemia. For other adhesion molecules, integrin alpha L chain (ITGAL) and integrin α2β1 has been found a higher probability to involve in severe thrombocytopenia in vivax malaria [
76]. The expression of molecules sharing an epitope with human ITGB2/LFA-1 integrin, or CD18 leukocyte integrin on the
Plasmodium falciparum-parasitized erythrocyte surface could be involved in the pathogenesis of severe disease [
77]. However, further studies are need to explore the association of these intercellular adhesion molecules with ezrin in vivax malaria.
In addition, ERM proteins are members of the band 4.1 superfamily, FERM (four-point one, ezrin, redixin, moesin) [
78-
80]. Phosphorylation of erythrocyte protein 4.1 is involved with the modification of the host erythrocyte membrane by
P. falciparum [
81]. Moreover, tyrosine phosphorylation of band 3, band 4.2, catalase and actin in
P. falciparum-infected erythrocytes are predicted to be part of the regulatory mechanism to modify the erythrocyte membrane [
82]. This study found low levels of alpha actinin-1 in gECs in the presence of IE. The subsequent reassembly of actin structure in response to parasite suppression is currently being investigated. This poorly understood aspect of ezrin function suggests that parasites inhibit the ezrin protein allowing the assembly of complex cellular structures in erythroid cells leading to dyserythropoiesis, inhibition of erythroid cell growth and division resulting in the accumulation of cells in a resting G0 phase. This study demonstrates that
vivax parasites suppress development of erythroid progenitor cells through a mechanism that includes decreased ezrin phosphorylation.
Plasmodium vivax is able to enter bone marrow, as previously reported [
17,
20,
57,
83], and parasites or its products bind to erythroid progenitor cells, resulting in decreased ezrin phosphorylation, leading to suppression of erythroid development, and ultimately anaemia. This is the first analysis suggesting that ezrin contributes to the suppression of erythroid cell growth by
P. vivax. Further investigation of this mechanism should help to better understand pathogenesis of anaemia in acute or chronic
P. vivax infection.
Acknowledgements
This study was supported by Thailand Research Fund, Commission on Higher Education, Ministry of Education and Suan Dusit Rajabhat University, (MRG5680064). I would like to thank the Department of Pathobiology, Faculty of Science for excellent technical assistance, Ramathibodi Hospital, Faculty of Medicine for collecting cord blood, the Division of Medicine Siriraj Hospital, Mahidol University for use of the laser scanning confocal microscope, Malaria Clinic in Tha Sae, Chumpon Province for parasite collection, Prof. Sumalee Tungpradubkul for scientific comments and suggestions and Dr. Laran Jensen for critical reading of this manuscript, Department of Biochemistry, Faculty of Science, Mahidol University.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
TP designed the study, collected parasites from patient blood, performed cell culture and other experiments, performed statistical analysis, and wrote the manuscript. SP performed bioinformatic analysis. SR supported laboratory facilities for proteomic analysis. AP and SK performed LC-MS/MS. SH and RU contributed substantially to design of experiments and gave advice for writing of the manuscript. All authors read and approved the final manuscript.